Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zocor Falls Off Formularies As Part D Plans Shift Patients To Generic Statins

Executive Summary

Zocor dropped quickly off of Part D formularies after having enjoyed wide preferred coverage in 2006, an analysis of 2007 Part D basic plan coverage of the statin group of cholesterol-lowering drugs indicates

You may also be interested in...



Merck Pushes Discount Zocor; Health Plans Are Wary, But Pfizer Is Concerned

The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward

Merck Wins Part D Cholesterol Therapy Formulary Battle; Lipitor In Retreat?

Merck appears to be the big winner in the Medicare Part D formulary placement battle for cholesterol-lowering therapies, according to an analysis of plan formularies conducted by the "The Pink Sheet."

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel